Inactive Instrument

BioTelemetry, Inc. Stock

Equities

BEAT

US0906721065

Healthcare Facilities & Services

Dynamic Chart
Ayala Pharmaceuticals, Inc. announced that it has received $2 million in funding from Israel Biotech Fund, Arkin Bio Venture Partners Ltd., BioTelemetry, Inc. CI
Ayala Pharmaceuticals, Inc. entered into a definitive merger agreement to acquire BioSight Ltd from Israel Biotech Fund, BioTelemetry, Inc., Arkin Bio Venture Partners Ltd., Primera Capital, SBI JI Innovation Advisory Ltd., Migdal Insurance Company Ltd., The Phoenix Insurance Company Ltd. and others. CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P Health Care Services Select Industry Index CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P 600 CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P Composite 1500 CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P 600 Health Care Services (Sub Ind) CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P 1000 CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P TMI Index CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P Global BMI Index CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from S&P 600 Health Care CI
BioTelemetry, Inc. Announces Board Changes CI
BioTelemetry, Inc. Terminates Amended and Restated Credit Agreement CI
Koninklijke Philips N : Royal Philips Completes Tender Offer to Acquire BioTelemetry at $72 per Share MT
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from NASDAQ Composite Index CI
BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from Russell 2000 Defensive Index CI
More news
Managers TitleAgeSince
Human Resources Officer - 17-06-30
Corporate Officer/Principal 54 09-05-31
More insiders
BioTelemetry, Inc. is a remote medical technology company focused on delivery of health information. The Company is principally engaged in providing remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring, and original equipment manufacturing that serves both healthcare and clinical research customers. The Company operates in two segments: Healthcare and Research. The Healthcare segment is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices. It offers cardiologists, electrophysiologists and primary care physicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials.
More about the company